Hepatocellular carcinoma treated with sorafenib: Early detection of treatment response and major adverse events by contrast-enhanced US

Liver International

Volumn 33, Issue 4, 2013, Pages 605-615

  Sugimoto, Katsutoshi ^a   Moriyasu, Fuminori ^a   Saito, Kazuhiro ^a   Rognin, Nicolas ^b   Kamiyama, Naohisa ^c   Furuichi, Yoshihiro ^a   Imai, Yasuharu ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Toshiba Medical Research Institute USA Inc   (United States)

^c TOSHIBA MEDICAL SYSTEMS CORPORATION   (Japan)

Author keywords

Adverse event; Contrast media; Dose escalation; Hepatocellular carcinoma; Sorafenib; Ultrasound

Indexed keywords

SORAFENIB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DYNAMIC CONTRAST ENHANCED ULTRASOUND; ECHOGRAPHY; ERYTHEMA MULTIFORME; FATIGUE; FEMALE; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LIVER FAILURE; MALE; OVERALL SURVIVAL; PANCREATITIS; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT RESPONSE; VOICE;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; AREA UNDER CURVE; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DISEASE-FREE SURVIVAL; FEMALE; FERRIC COMPOUNDS; HUMANS; IRON; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; OXIDES; PERFUSION IMAGING; PHENYLUREA COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84875053147     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12098     Document Type: Article

References (33)

1. Kudo M. The 2008 Okuda lecture: management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010; 25: 439-52.
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Eng J Med 2008; 359: 378-90.
3. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
4. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: micro-vessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94: 883-93.
5. Padhani AR, Neeman M. Challenges for imaging angiogenesis. Br J Radiol 2001; 74: 886-90.
6. Schramm C, Schuch G, Lohse AW. Sorafenib-induced liver failure. Am J Gastroenterol 2008; 103: 2162-3.
7. Rombolà F, Caravetta A, Mollo F, et al. Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case. Acta Medica (Hradec Kralove) 2011; 54: 177-9.
8. Huang WS, Yang CH. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol 2009; 15: 4464-6.
9. Lassau N, Koscielny S, Chami L, et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification - preliminary results. Radiology 2011; 258: 291-300.
10. Sugimoto K, Saito K, Honjo M, et al. A case of advanced hepatocellular carcinoma who died of metabolic encephalopathy early in the course of treatment with sorafenib with marked changes in imaging findings. Kanzo 2010; 51: 227-35.
11. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
12. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
13. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
14. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS. Available at http://ctep.cancer.gov. Published March 31, 2003, and August 9, 2006. Accessed September 2011.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
16. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
17. Rognin NG, Arditi M, Mercier L, et al. Parametric imaging for characterizing focal liver lesions in contrast-enhanced ultrasound. IEEE Trans Ultrason Ferroelectr Freq Control 2010; 57: 2503-11.
18. Anaye A, Perrenoud G, Rognin N, et al. Differentiation of focal liver lesions: usefulness of parametric imaging with contrast-enhanced US. Radiology 2011; 261: 300-10.
19. Lassau N, Koscielny S, Albiges L, et al. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 2010; 16: 1216-25.
20. Lassau N, Lamuraglia M, Chami L, et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 2006; 187: 1267-73.
21. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-86.
22. Bergers G, Hanahan D. Models of resistance to antiangiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
23. Mejias M, Garcia-Pras E, Tiani C, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-56.
24. Reiberger T, Angermayr B, Schwabl P, et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol 2009; 51: 865-73.
25. Coriat R, Gouya H, Mir O, et al. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS ONE 2011; 6: e16978.
26. Ogasawara S, Kanai F, Obi S, et al. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int 2011; 5: 850-6.
27. Iavarone M, Cabibbo G, Piscaglia F, et al.; SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54: 2055-63.
28. Kim JE, Ryoo BY, Ryu MH, et al. Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. Oncology 2012; 82: 119-25.
29. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118: 147-56.
30. Ng CS, Raunig DL, Jackson EF, et al. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am J Roentgenol 2010; 194: W134-40.
31. 2 positron emission tomography measurements of blood flow in patients with intra-abdominal cancers. Clin Cancer Res 2003; 9: 6350-6.
32. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. Dynamic CT measurement of cerebral blood flow: a validation study. AJNR Am J Neuroradiol 1999; 20: 63-73.
33. Gauthier M, Leguerney I, Thalmensi J, et al. Estimation of intra-operator variability in perfusion parameter measurements using DCE-US. World J Radiol 2011; 3: 70-81.